Not all drugs are the same;Droge ist nicht gleich Droge

Medizinische Klinik - Intensivmedizin und Notfallmedizin

Volumn 108, Issue 6, 2013, Pages 484-490

  Weilemann, L S ^a  

^a NONE   (Germany)

Author keywords

Antidotes; Designer drugs; Drugs; Therapy; Toxicology

Indexed keywords

AMPHETAMINE DERIVATIVE; CANNABINOID; CATHINONE; COCAINE; DESIGNER DRUG; DIAMORPHINE; ANTIDOTE; STREET DRUG;

ARTICLE; DRUG INTOXICATION; DRUG USE; HUMAN; LEGAL ASPECT; DIAGNOSIS; DOSE RESPONSE; INTOXICATION; RISK FACTOR; THERAPY;

ANTIDOTES; DESIGNER DRUGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; POISONING; RISK FACTORS; STREET DRUGS;

EID: 84884674529     PISSN: 21936218     EISSN: 21936226     Source Type: Journal    
DOI: 10.1007/s00063-013-0219-1     Document Type: Article

References (17)

1. Absalon N, Eghorst LF, Villumsen IS (2012) GABA receptors are high-affinity targets for gamma hydroxybuturic acid. Proc Natl Acad Sci U S A 109(33):13404-13409
2. Auwärter V et al (2009) Spice and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44(5):832-837
3. Castellanos D, Thornton G (2012) Synthetic cannabinoid use: recognition and management. J Psychiatr Pract 18:86-93
4. European Monitoring Centre for Drugs and Drug Addiction (2009) Understanding spice phenomenon, thematic papers. http://www.emcdda.europa.eu (Zugegriffen: 23.07.2013)
5. Gibbons S, Zloh M (2010) An analysis of the "legal high" mephedrone'. Bioorg Med Chem Lett 20(14):4135-4139
6. Green AR (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55:S463-S508
7. Gouzulis-Mayfrank E et al (2002) Neurotoxische Langzeitschäden bei Ecstasy (MDMA) Konsum. Überblick über den derzeitigen Wissensstand. Nervenarzt 73:405-472
8. Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V (2013) Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 108:534-544
9. http://bka.de. Dokument Rauschgiftkriminalität. Zugegriffen Mai 2013
10. http://www.emcdda.europa.eu/edr. Zugegriffen Mai 2013
11. http://www.homeoffice.gov.uk/publications/drugs/acmd1/acmd-cathinodes-report-2010. Zugegriffen Mai 2013
12. Huffmann JW (2009) Cannabimimetic indoles, pyrroles and indenes. Structure activity relationships and receptor interactions. In: Reggio PH (Hrsg) The cannabinoid receptors. Humana Press, Totowa NJ
13. Kupferschmidt H (2012) Neue Drogen. Praxis 101:565-570
14. Meyer MR, Peters FT, Maurer HH (2009) Metabolism of the new designer drug mephedrone and toxicological detection of the beta keto designer drugs mephedrone, butylone and methylone in urine. Annales de Toxicologie Analytique 21
15. Sauer O, Weilemann LS (2000) Drogen-Eigenschaften-Wirkungen-Intoxikationen. Schlütersche, Hannover
16. Sauer O, Weilemann LS (2002) Biogene Drogen und Designerdrogen. Intern Prax 42:345-382
17. Snead OC, Gibson KM (2005) Gamma-Hydroxybuturic acid. N Engl J Med 352:2721-2732